BioNTech (NASDAQ:BNTX – Get Rating) and Protara Therapeutics (NASDAQ:TARA – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.
Analyst Ratings
This is a summary of current ratings and target prices for BioNTech and Protara Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioNTech | 0 | 8 | 6 | 0 | 2.43 |
| Protara Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
BioNTech currently has a consensus price target of $231.43, indicating a potential upside of 73.22%. Protara Therapeutics has a consensus price target of $28.50, indicating a potential upside of 755.86%. Given Protara Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than BioNTech.
Risk and Volatility
BioNTech has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Insider & Institutional Ownership
13.8% of BioNTech shares are held by institutional investors. Comparatively, 52.6% of Protara Therapeutics shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 15.2% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares BioNTech and Protara Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioNTech | 55.43% | 88.76% | 66.03% |
| Protara Therapeutics | N/A | -25.59% | -24.08% |
Valuation and Earnings
This table compares BioNTech and Protara Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioNTech | $22.45 billion | 1.44 | $12.18 billion | $51.78 | 2.58 |
| Protara Therapeutics | N/A | N/A | -$47.25 million | ($3.63) | -0.92 |
BioNTech has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.
Summary
BioNTech beats Protara Therapeutics on 9 of the 13 factors compared between the two stocks.
About BioNTech
(Get Rating)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
About Protara Therapeutics
(Get Rating)
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Receive News & Ratings for BioNTech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioNTech and related companies with MarketBeat.com’s FREE daily email newsletter.
